Catalyst
Slingshot members are tracking this event:
Boston Scientific Receives U.S. FDA Approval For Blazer Open-Irrigated Catheter
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BSX | Community voting in process |
Additional Information
The Blazer OI catheter was granted approval based on data from the BLOCk-CTI clinical trial, a prospective, randomized trial that enrolled 302 patients at 24 sites in the U.S. and evaluated the safety and effectiveness of the Blazer OI catheter in patients with sustained or recurrent Type 1 atrial flutter.
In January, the company also received CE Mark for the IntellaTip MiFi open-irrigated (OI) catheter for use in all cardiac ablation procedures. The IntellaTip MiFi OI catheter is designed to provide physicians precise, multidimensional information via mini-electrodes which deliver a highly localized signal reflecting exactly what is happening at the tip of the catheter in real-time during the ablation procedure. The IntellaTip MiFi OI catheter also features the same Total Tip Cooling technology as the Blazer OI catheter.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ce Mark, Block-cti, Open-irrigated Catheter, Atrial Flutter, Heart Muscle, Heart Rhythm, Total Tip Cooling, Radiofrequency Ablation Catheter, Blazer Oi Catheter